Colleen Goggins
Director at IQV
Board
About Colleen A. Goggins
Independent director at IQVIA since 2017 (age 70), currently Chair of the Nominating & Governance Committee (N&G) and member of the Audit Committee. Former member of Johnson & Johnson’s Executive Committee and Worldwide Chair of its Consumer Group, with board experience across healthcare, financial services, and global corporates. Education: Masters in Management, Kellogg School of Management; B.S. in Food Chemistry, University of Wisconsin–Madison . The Board classifies all directors other than the CEO as independent; committees are 100% independent .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Johnson & Johnson | Member, Executive Committee; Worldwide Chair, Consumer Group | Not disclosed | Senior operating leadership in global healthcare consumables |
| SIG Combibloc Group | Advisory Board Member; then Director | 2015–2017 (Advisory); 2018–2023 (Director) | Board governance in packaging/industrial; European market exposure |
External Roles
| Organization | Role | Tenure | Committees/Notes |
|---|---|---|---|
| Bayer AG | Member, Supervisory Board | 2017–present | German two‑tier board oversight in pharma/life sciences |
| The Toronto‑Dominion Bank | Director | Not disclosed | Risk Committee member |
| Bausch Health Companies Inc. | Director (prior) | Not disclosed | U.S. public company board experience |
| Citymeals‑on‑Wheels (NYC) | Member | Not disclosed | Non‑profit governance |
| University of Wisconsin Foundation | Member | Not disclosed | Non‑profit/academic foundation oversight |
| Institute of International Education | Trustee | Not disclosed | Global academic/non‑profit governance |
Board Governance
- Committee leadership and assignments: Chair, Nominating & Governance Committee (N&G); Member, Audit Committee .
- Committee activity: N&G met 4 times in 2024; Audit met 6 times in 2024 .
- Sustainability oversight and engagement: As N&G Chair, Goggins coordinates Board‑level oversight of sustainability, meets regularly with management, and engages stockholders on ESG reporting/priorities, reporting back to the Board; she coordinates closely with the Lead Independent Director on these topics .
- Independence and structure: All directors except the CEO are independent; all three standing committees (Audit, LDC, N&G) are fully independent .
- Attendance: The Board held 4 meetings in 2024; each director attended at least 75% of Board and committee meetings on which they served .
- Board refreshment and policy: Annual election, majority voting with resignation policy in uncontested elections; director retirement policy at age 74 .
Fixed Compensation (Non‑Employee Director)
| Component | Amount ($) | Notes |
|---|---|---|
| Annual cash retainer | 100,000 | Standard cash retainer |
| Audit Committee member fee | 15,000 | Member (non‑chair) |
| N&G Committee chair fee | 25,000 | Committee chair |
| Total cash earned (2024) | 140,000 | Equals 100,000 + 15,000 + 25,000 |
| Cash deferral election | 100% deferred | Deferred into DSUs under Director Deferral Plan |
Notes: Director compensation program reimburses reasonable education/travel; no per‑meeting fees disclosed .
Performance Compensation (Non‑Employee Director)
| Element | 2024 Grant Details | Vesting/Performance | Accounting/Other |
|---|---|---|---|
| Annual equity retainer (RSUs) | 1,047 RSUs granted May 7, 2024; grant‑date fair value $239,910 ($229.14/share) | Fully vested when granted; no performance metrics | Determined under ASC 718; equity granted as fully‑vested RSUs; some directors defer into DSUs (Goggins did not defer the 2024 equity) |
Notes: Non‑employee director equity is not performance‑based; the company prohibits hedging/pledging and maintains ownership guidelines (see Equity Ownership) .
Other Directorships & Interlocks
| Company | Sector Relationship to IQVIA | Potential Interlock Consideration |
|---|---|---|
| Bayer AG (Supervisory Board) | Large global pharma; IQVIA states partnerships with 22 of the top 25 pharma companies | If IQVIA provides services to Bayer, perceived related‑party sensitivity could arise; Audit Committee oversees related‑party transaction approval . |
| The Toronto‑Dominion Bank (Risk Committee) | Financial services | No direct business linkage disclosed in proxy; standard RPT oversight applies . |
| Bausch Health (prior) | Pharma/healthcare | Historical service; no transactions disclosed in excerpts reviewed . |
The proxy details the policy and Audit Committee responsibility for reviewing/approving any related‑party transactions; the excerpts reviewed do not describe any specific transactions involving Ms. Goggins .
Expertise & Qualifications
- Healthcare operating leadership: Senior executive experience at J&J; “Healthcare” listed as a key skill in director matrix .
- Public company governance: Service on multiple public boards; “Public Company Board” and “Financial” skills designated in director matrix .
- Technology/data and global experience: “Technology” and “Global” skills designated; supervisory/board roles across multinational organizations .
- Education: Masters in Management (Kellogg); B.S. Food Chemistry (UW‑Madison) .
Equity Ownership
| Item | Detail |
|---|---|
| Total beneficial ownership (1/31/2025) | 15,238 shares; less than 1% of shares outstanding |
| Breakdown | 11,290 shares issued pursuant to Company stock incentive plans; 3,948 notional DSUs under the Director Deferral Plan |
| Director ownership guideline | 5x annual cash retainer; all director nominees subject to the guideline met the requirement as of 2/24/2025 |
| Hedging/pledging policy | Company prohibits hedging and pledging of Company shares without exception |
| Deferral elections | Deferred 100% of 2024 cash retainers/committee fees into DSUs; total DSUs outstanding 3,948 as of 12/31/2024 |
Governance Assessment
- Strengths supporting investor confidence:
- Independent director with deep healthcare operating experience; chairs N&G and leads sustainability oversight/stockholder engagement on ESG with clear Board‑level mandates .
- Ownership alignment: meets 5x retainer guideline; meaningful beneficial ownership and DSUs; anti‑hedging/pledging policy enhances alignment .
- Committee effectiveness: Active roles on two key committees; N&G met 4x; Audit met 6x in 2024; committee membership fully independent .
- Attendance: Board reported each director attended at least 75% of Board/committee meetings in 2024 .
- Potential watch‑items:
- External board service at a major pharma (Bayer AG) creates potential related‑party sensitivity if IQVIA provides services to such counterparties; the Audit Committee is responsible for reviewing/approving any related‑party transactions; the excerpts reviewed do not disclose specific RPTs involving Ms. Goggins .
- Board retirement policy at age 74 suggests eventual refresh over the medium term (Goggins age 70), which is positive for renewal but introduces succession planning consideration at the committee chair level .
- Broader shareholder sentiment on compensation/governance remains constructive (84% say‑on‑pay support in 2024), indirectly supportive of governance credibility during her tenure .
Overall, Ms. Goggins’ committee leadership, independence, sustained engagement on sustainability, and compliance with ownership guidelines support board effectiveness; any perceived interlocks should be monitored via the company’s established related‑party transaction review controls .